2 S&P 500 Stocks Worth Investigating and 1 Facing Headwinds
IQVIA Holdings has outperformed the Dow over the past year, and analysts are highly optimistic about the stock’s prospects.
Q1 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €950,000,000 in aggregate principal amount of senior...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €950,000,000 through an offering of senior notes due 2033...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced...
While IQVIA Holdings has lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
1 Mid-Cap Stock Worth Your Attention and 2 We Question
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration...
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know